Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 9/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890737 | 0.89 | ICMT (0.44) | ICMTPTGS2PTGS1CYP2C19 | |
| SCHEMBL2393685 | 0.87 | KCNA5 (0.43) | ICMTPTGS2CYP2C19 | |
| SCHEMBL6184923 | 0.82 | CYP2C19 (0.64) | PTGS2PTGS1CYP2C19 | |
| SCHEMBL2393760 | 0.81 | CHRM1 (0.56) | CYP2C19SLC9A1CHRM1CHRM3 | |
| SCHEMBL9289358 | 0.80 | PTGS2 (0.57) | PTGS2PTGS1CYP2C19CHRM1CHRM3 | |
| SCHEMBL2391279 | 0.80 | CYP2C19 (0.48) | ICMTCYP2C19SLC9A1CHRM1CHRM3 | |
| SCHEMBL2393365 | 0.80 | CYP2C19 (0.43) | ICMTPTGS2CYP2C19CHRM1CHRM3 | |
| SCHEMBL2390396 | 0.80 | KCNJ5 (0.49) | CYP2C19 | |
| SCHEMBL2397118 | 0.79 | CHRM3 (0.44) | ICMTCYP2C19CHRM1CHRM3 | |
| SCHEMBL2395669 | 0.79 | ATR (0.39) | ICMTPTGS2CYP2C19CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885PTGS2 2051/4885PTGS1 2007/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885PTGS2 2051/4885PTGS1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.